Simplified Academic Research Consortium for High Bleeding Risk (ARC-HBR) Definition Predicts Bleeding Events in

Yu Sato1, Akiomi Yoshihisa1,2, Ryohei Takeishi1

  • 1Department of Cardiovascular Medicine, Fukushima Medical University.

Insights

The simplified Academic Research Consortium for High Bleeding Risk (ARC-HBR) definition effectively identifies patients with heart failure (HF) at high risk for bleeding events after hospital discharge.

Area of Science:

  • Cardiology
  • Clinical Research
  • Patient Risk Stratification

Background:

  • The simplified Academic Research Consortium for High Bleeding Risk (ARC-HBR) definition was previously validated for patients with coronary artery disease (CAD).
  • Its applicability to patients with heart failure (HF) for identifying high bleeding risk (HBR) was not established.

Purpose of the Study:

  • To evaluate the utility of the simplified ARC-HBR definition in identifying high bleeding risk (HBR) in patients hospitalized for heart failure (HF).

Main Methods:

  • A cohort of 2,437 patients hospitalized for HF was analyzed.
  • Patients were classified as HBR or non-HBR using the simplified ARC-HBR definition.
  • Post-discharge bleeding events (hemorrhagic stroke, gastrointestinal bleeding) were tracked.

Main Results:

  • 83.1% of HF patients met the simplified ARC-HBR criteria for high bleeding risk.
  • The HBR group was significantly older and had a lower prevalence of CAD.
  • Post-discharge bleeding events were significantly more frequent in the HBR group (log-rank P<0.001).
  • The simplified ARC-HBR definition accurately predicted bleeding events (HR 2.777, P=0.001).

Conclusions:

  • The simplified ARC-HBR definition is a valuable tool for predicting bleeding risk in heart failure patients.
  • This definition can aid in identifying HF patients who may benefit from closer monitoring or tailored management strategies to prevent bleeding.
Abstract

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
200
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
261
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
293